AIFA IMPOSES BAN ON USE OF ASTRAZENECA BATCH

INVESTIGATIONS IN PROGRESS IN COORDINATION WITH EMA

Following the reporting of some serious adverse events, in temporal concomitance with the administration of doses belonging to batch ABV2856 of the AstraZeneca anti-COVID-19 vaccine, AIFA has decided, as a precaution, to issue a ban on the use of this lot throughout the national territory and reserves the right to take further measures, if necessary, also in close coordination with the EMA, the European Medicines Agency.

At present, no causal link has been established between the administration of the vaccine and these events.

AIFA is carrying out all the necessary verifications, acquiring clinical documentation in close collaboration with the NAS and the competent authorities. The samples of this batch will be analysed by the Istituto Superiore di Sanità.

AIFA will promptly communicate any new information that becomes available.